Search

everythinglearnresearchcommunity

for

Search:↓

Weekly azathioprine pulse is a better alternative to corticosteroids for treating alopecia areata due to fewer side effects.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.

Simvastatin/ezetimibe may help treat new cases of alopecia areata but not long-term cases.

Recognizing and treating skin symptoms in essential thrombocythemia is crucial for patient quality of life.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

New medications could improve treatment for severe alopecia areata in Australia.

Chronic refractory alopecia areata has more skin-resident memory T cells, and JAK inhibitors may help reduce them.

New treatments like JAK inhibitors offer hope for better alopecia areata management.

Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.

Stopping adalimumab and starting methotrexate with topical treatments improved the woman's scalp psoriasis and hair regrew.

Baricitinib is effective as a treatment for severe hair loss.

Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Baricitinib was effective in treating both early and late onset alopecia areata.

Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

Mixing platelet-rich plasma with triamcinolone acetonide can potentially improve hair regrowth in alopecia areata patients.

Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.

The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

All four treatments for early rheumatoid arthritis had similar safety profiles.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Combining high-dose corticosteroids with methotrexate may be effective and safe for severe alopecia areata.

Cryotherapy with precise temperature control is a promising treatment for alopecia areata.